Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
MORF Price Action
MORF RSI Chart
MORF Valuation
MORF Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
MORF Fundamentals
MORF Revenue
MORF Earnings
MORF Profitability
MORF Investor Care
Revenue & Growth
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 53.2M | 35.7M | 18.1M | 521.0K |
| 2022 | 32.5M | 45.3M | 58.1M | 70.8M |
| 2021 | 42.6M | 38.8M | 16.1M | 19.8M |
| 2020 | 24.0M | 31.0M | 38.0M | 44.9M |
| 2019 | 9.1M | 14.9M | 20.7M | 17.0M |
| 2018 | 0 | 0 | 0 | 3.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| CEO | Dr. Praveen P. Tipirneni M.D. |
|---|---|
| WEBSITE | morphictx.com |
| SECTOR | Healthcare |
| INDUSTRY | Biotechnology |
| EMPLOYEES | 110 |
